Funding Resources
Funding Overview
Funding Strategy
Funding Opportunities
Grant Mechanisms
Training & Career
Development
Contracts Management
Review Committees
Funding News
Program Areas
Research
Anticonvulsant Screening
Program
Clinical Research
Counterterrorism |
NINDS is part of the
National Institutes of
Health
CounterACT Website |
---|
CounterACT News Alerts
3rd Annual CounterACT Network Research Symposium
Tuesday April 14th - Thursday April 16, 2008
Omni Shoreham Hotel
2500 Calvert Street NW (at Connecticut Ave.), Washington, D.C. 20008
Supplemental research currently supported by the 2008 CounterACT Administrative Supplement Program
Behavioral Effects of Low Doses of Nerve Agents Are Counteracted by Galantamine: Potential Molecular Mechanisms (Edson Albuquerque)
Development of BAPTA-AM as a Counteract Agent (Robert DeLorenzo)
Polymer Nanogel Aggregates for Targeted Lung Delivery (Jeff Laskin & Pat Sinko)
(Please contact PI directly for additional information about these efforts).
Most Recent CounterACT Publications
Janciauskiene S, Nita I, Subramaniyam D, Li Q, Lancaster JR, Matalon S. (2008) Alpha1-antitrypsin inhibits the activity of the matriptase catalytic domain in vitro. Am J Respir Cell Mol Biol. [Epub ahead of print] Abstract
Leustik M, Doran S, Bracher A, Williams S, Squadrito GL, Schoeb TR, Postlethwait EM, Matalon S. (2008) Mitigation of chlorine induced lung injury by low molecular weight antioxidants. Am J Physiol Lung Cell Mol Physiol. [Epub ahead of print] Abstract
NIH Countermeasures Against Chemical Threats (CounterACT) Research Network
The increased risk of a terrorist attack in the United States involving chemical agents has created new challenges for many departments and agencies across the federal government. Within the Department of Health and Human Services (DHHS), the NIH is taking a leadership role in pursuing the development of new and improved medical countermeasures designed to prevent, diagnose, and treat the conditions caused by potential and existing chemical agents of terrorism. In addition, many of the same chemicals posing a threat as terrorist agents may also be released from transportation and storage facilities by industrial accidents or during a natural disaster. The NIH has developed a comprehensive CounterACT Research Network that includes Research Centers of Excellence, individual research projects, SBIRs, contracts and other programs. The CounterACT network will conduct basic, translational, and clinical research aimed at the discovery and/or identification of better therapeutic and diagnostic medical countermeasures against chemical threat agents, and their movement through the regulatory process. The overarching goal of this research program is to enhance our diagnostic and treatment response capabilities during an emergency. This program is a trans NIH effort, involving participation from the National Eye Institute, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Child Health and Human Development, National Institute of Environmental Health Sciences, National Institute of General Medical Sciences, and the National Institute of Neurological Disorders and Stroke.
Higher Priority Chemical Threats
Scope of Research
Special consideration will be given to research relevant to people who are particularly vulnerable, including the young, the elderly, and individuals with pre-existing medical conditions.
Contact Information
David A. Jett, Ph.D.
Program Director
National Institutes of Health, NINDS
6001 Executive Blvd.
NSC, Room 2177, MSC 9535
Bethesda, MD 20892-9535
Phone: 301-496-6035
jettd@ninds.nih.gov
Stacey D. Chambers
Program Analyst
National Institute of Health, NINDS
6001 Executive Blvd.
NSC, Room 2172, MSC 9521
Bethesda, MD 20892-9521
Phone: 301-496-0690
Fax: 301-402-1501
chambers@ninds.nih.gov
David T. Yeung, Ph.D.
Program Specialist
Northrop Grumman IT Health Solutions
at NIH/NINDS
6001 Executive Blvd.
NSC, Room 2195, MSC 9527
Bethesda, MD 20892-9527
Tel: 301-443-7534
yeungd@ninds.nih.gov
Last updated September 15, 2008